An O’Hara company that makes artificial heart pumps and related devices is closing by the end of the year, leaving 137 people out of work and ending production of a storied Pittsburgh biotech innovation.
LivaNova USA Inc., the British parent of TandemLife, formerly known as CardiacAssist Inc., has notified the state Department of Labor & Industry of the layoffs, which are to begin at the end of January and continue through the end of the year.
LivaNova called the closing an “orderly wind down” of the company’s Advanced Circulatory Support Business Unit, including Hemolung Systems, a product line that will be discontinued.
Hemolung Systems began in 1996 as a University of Pittsburgh spinout, then called ALung Technologies Inc. In 2020, ALung Technologies received Food and Drug Administration approval for the emergency use of the Hemolung device, the company’s signature product, in the treatment of COVID-19, which was then causing shortages of hospital ventilators.
The device removes carbon dioxide from the bloodstream from outside the patient’s body, and COVID-19 attacks the lungs where normal gas exchange takes place.
More than $100 million was invested in the company over the years without returns until the Food and Drug Administration approved the company’s artificial lung for marketing in November, 2021.
Six months after FDA approval, London-based LivaNova PLC acquired South Side-based ALung for $10 million, which was payable at closing and upon reaching certain sales milestones.
In a statement Monday, LivaNova said it anticipated supporting service for the Hemolung and LifeSPARC product platforms through the end of 2024. Production of other devices from the company’s Advanced Circulatory Support Unit, including arterial and venous cannulae insertion kits, will be shifted to LivaNova’s Cardiopulmonary Business Unit.
“We aim to make this transition as seamless as possible for our customers and employees,” LivaNova Interim CEO and Chair William Kozy said in a prepared statement.
LivaNova expected a pre-tax impairment charge ranging up to about $110 million during the fourth quarter of 2023 and restructuring charges between $15 million and $20 million, mostly this year, as the result of the shutdown.
The closure of the O’Hara business, which contributed about 4% of the company’s net revenue for the nine months ending Sept. 30, was expected to result in positive operating income in 2024. LivaNova employs about 2,900 employees and has a presence in more than 100 countries.
Kris B. Mamula: kmamula@post-gazette.com







Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.